CDT Equity (NASDAQ:CDT) Shares Set to Reverse Split on Monday, July 20th

Shares of CDT Equity Inc. (NASDAQ:CDT) are set to reverse split before the market opens on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, July 19th.

CDT Equity Stock Performance

CDT Equity stock traded up $0.00 during mid-day trading on Thursday, hitting $0.35. 888,099 shares of the company traded hands, compared to its average volume of 3,301,149. CDT Equity has a one year low of $0.30 and a one year high of $461.54. The stock has a market cap of $1.72 million, a price-to-earnings ratio of -0.00 and a beta of 1.49. The stock has a fifty day moving average price of $0.92 and a 200-day moving average price of $12.33.

CDT Equity (NASDAQ:CDT) last posted its quarterly earnings data on Wednesday, July 15th. The company reported ($5.56) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CDT shares. Wall Street Zen lowered CDT Equity to a “strong sell” rating in a research report on Saturday, June 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of CDT Equity in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.